

Equity Research Department – Healthcare

Analysts

Bach Hoang Nguyen Analyst, Equity Research bachnguyen@u.nus.edu

Li Aiyu

Analyst, Equity Research <u>aiyu.li@u.nus.edu</u>

Basic Information

Ticker	MASI
Last close (221209)	US\$138.49
12M Target Price	US\$151.27
+ / - Potential	+9.2%
GICS Sector	Healthcare
GICS Subindustry	Healthcare Equipment
	& Supplies





Company Description

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including non-invasive innovative measurements, sensors, and patient monitors.

Key Financials												
Market Cap		US\$6.831										
Basic Shares ()/S			52.5M								
Free Float				82.9%								
52-Wk High-L	ow	US\$10	8.89 - US	\$305.00								
Fiscal Year En	d		31-D	ec-2022								
(US\$ M)	FY19A	FY20A	FY21A	FY22E								
Revenue	938	1,144	1,239	2,019								
Gr Rate (%)	9.3	22.0	8.3	63.0								
EBIT	234.2	263.7	274.4	214.8								
Margin (%)	25.0	23.1	22.1	10.6								
NPI	196.2	240.3	229.6	132.5								
Margin (%)	20.9	21.0	18.5	6.6								
ROE (%)	16.8	17.1	14.8	9.2								

Key Executives

Joe Kiani Micah Young Chief Executive Officer Chief Financial Officer Date: 13rd Dec 2022

We are initiating coverage of **Masimo Corporation**, ("MASI" or "Masimo") with a BUY rating and a <u>US\$151.27</u> 12M price target.

3Q22 Earnings Highlights

- Healthcare segment saw a 6.4% revenue growth to US\$327.2m compared to prior year period.
- MASI shipped approximately 76,100 technology boards and instruments as compared to 74,600 in 3Q21.
- Consumer audio segment revenue reported at US\$222.1m, representing a 6.6% increase vs. previous quarter.
- Net income stood at US\$37.9m, a decrease of 34.4% as compared to prior year period.

Investment Thesis

- Masimo's acquisition of Sound United seems to be an unrelated move at first glance, but in fact it represents an underappreciated opportunity by the market – despite being undervalued at the moment, the decision has shown the management's foresight and implied a hospital-to-home healthcare strategy to shift to consumer market
- Current monitoring system landscape in Hospitals' general wards imply a large addressable market for Masimo – The company can leverage upon its dominant share in pulse oximetry business to capture this largely untapped market and build longterm growth and value

Catalysts

- The ongoing lawsuit between the company and Apple is expected to shed Masimo in a positive light if Masimo wins
- Submitted 510(k) application for W1 watch is expected to get approved soon for full launch of the product
- The surge in of respiratory illnesses among vulnerable communities might affect government's policies and hospitals' expenditure on medical equipment
- Announcement of progress of the new project between engineering teams from the company and Sound United may restore investors' confidence


Valuations

Our 12M target price at the date of coverage is <u>US\$151.27</u>, consisting of a blend between a DCF valuation of **US\$146.34** and a blended multiple valuation of **US\$156.19**.

Investment Risks


- Inflation erodes consumer spending, cutting consumer audio segment revenue
- Lower capex from hospitals translates into less revenue for MASI' core business
- Lack of integration synergy with respect to audio technology

Figure 1: MASI's Products Evolution



Source: Company Websites

Figure 2: Geographical Revenue Mix



Source: Company Filings

Company Overview

Founded in 1989, Masimo Corporation ("MASI") is a global medical equipment company that concentrates on developing and selling noninvasive monitoring technology and hospital management solutions to professional healthcare providers. The company both produces its own monitoring equipment and licenses its technology to other major MedTech companies such as Phillips, GE Healthcare, Baxter International, etc.

In 1995, MASI successfully developed and debuted its proprietary Signal Extraction Technology ("SET"), allowing for high-accuracy measurement under extreme body condition – low perfusion and constant motion. Up till date, SET-based pulse oximetry has become an industry standard, and it is used to monitor over 200 million patients worldwide annually. Through more than 2 decades of operation, MASI's product portfolio has seen vertical and horizontal expansion from traditional SET-based monitoring devices to going beyond pure-play oxygen measurement into other segments including brain function monitoring, nasal flow gauging, and substance-addiction tracking system (Figure 1).

MASI sells its products through three main channels: (i) selling directly to end-user hospitals and healthcare operators, (ii) selling to third-party distributors, and (iii) selling circuit boards to OEM partners. Direct sales and distribution channels accounted for 88.7% of total revenue in 2021, amounting to US\$1,099.1m while partnership with OEM contributed US\$140.1m in revenue. Geographically, MASI derived a dominant portion of revenue from the U.S market, followed by Europe and EMEA market (Figure 2).

MASI manufactures end-user products mostly in-house with one facility in U.S and two facilities in Mexico. For subassembly parts such as the circuit boards, the process is outsourced to third-party manufacturers. MASI and its contractors rely on sole source suppliers for certain main components, including digital signal processor chips and analog-to-digital converter chips.

FY22 development: On April 11, 2022, MASI successfully acquired 100% of equity interest of Sound United for US\$1.065 billion, primarily financed by MASI's new credit facility. Sound United is a holding company of many premium and high-performance audio brands (Figure 3). The consumer audio segment is expected to contribute around one-third of total revenue annually for the combined business.

3Q22 earnings highlights:

- Healthcare segment revenue: MASI is seeing a 6.4% increase compared to prior year period, resulting in US\$327.2m.
- As compared to 2Q22, healthcare revenue resembled an 8.3% drop; however, historical performance has demonstrated similar pattern. Main reasons can be attributed to rampant growth in 2Q22 to solve backlog orders in 1Q22 while 3Q22 was seeing less surgery and procedures carried out in hospitals as compared to other periods, thus contributing to slower sales of single-use sensors to hospitals.
- MASI shipped approximately 76,100 technology boards and instruments as compared to 74,600 in 3Q21. The company is on


Figure 3: Sound United's Brands Portfolio

Bowers & Wilkins



Source: Company Websites

Figure 4: Size of the Global Pulse Oximeter Market



Source: Grandview Research

Figure 5: Problems Addressable by Home Healthcare



Source: Frost & Sullivan

track for a full-year shipment of around 300,000 – an 3.8% YoY increase.

- Consumer audio revenue: reporting US\$222.1 in total sales, a 6.6% increase as compared to 2Q22.
- Full-year guidance: Management is expecting revenue of US\$675m for consumer audio and US\$1,325m for healthcare, culminating in US\$2 billion.
- Top-line margin decreased due to the new business line, primarily because of the difference in COGS for each segment 64.6% for healthcare and 35.0% for consumer audio, resulting in a combined gross margin of 51.4%. Moreover, FX and operation headwinds is expected to contribute 3% in negative effect for full year gross margin.
- Main operating expense margin showed signs of improvement, with 31.8% for SG&A margin and 9.7% for R&D margin. Threeyear quarterly average for 2019 – 2021 period stood at 32.6% and 10.5% for SG&A and R&D margin respectively.
- Net income stood at US\$37.9m, a decrease of 34.4% as compared to prior year period. Net margin also declined to 6.9% from 18.8% on a QOQ-basis. Leading factor was the aforementioned top-line compression in gross margin.


Industry Outlook

The size of the global pulse oximeter market is around \$2.3 billion dollars in 2020, and from 2021 to 2028 its expected to grow at a CAGR of 6.4%, driven by both increasing prevalence of home healthcare and consistent increase in demand for healthcare services in hospitals since hospitals and individual patients are the main end-users of pulse oximeters. Although pulse oximetry is not covered under Medicare, the CARES Act passed in March 2020 has incentivised the suppliers to produce and distribute products by providing additional liability protection and using attractive financial incentives to support hospitals for diagnostics, screening and treatment (Figure 4).


Burgeoning popularity of home healthcare


Home healthcare refers to a wide range of services that can be provided to patients at home for illnesses and injuries such as wound care for surgical wounds, patient and caregiver education and monitoring of serious illnesses and unstable health status. According to research, home healthcare has been growing fast driven by technological according to research because it can addressed three significant problems associated with hospital admissions: 1) preventing Hospital Admission Infection (HAI) by using devices only for the patients being treated so they are not exposed to other patients, 2) improving healing and recovery time attributed to familiarity of the home setting and presence of relatives during treatment which can reduce stress, and 3) providing more effective care with one-to-one basis care offered unlike in hospitals where professionals have to cater to multiple patients, which would improve the overall efficiency of in-hospital care as well by freeing up beds and reducing stress on the professionals (Figure 5). In the United States, around 33% of the clinicians believe that by 2031, healthcare services including critical care, acute care and chronic care will be provided at the patient's home driven by rising prevalence of chronic diseases with age-related conditions, patients' own preferences, payment reforms from volume under fee-for-service to outcomes under valuebased care so that healthcare providers also share financial risk with

Figure 6: Yearly U.S. Total Hospital Admission



Source: American Hospital Association





Source: American Hospital Association

payers to ensure quality as well as development in technology to improve portability of medical equipment so that they can be transported and set up at home.

Tech firms' growing interest in remote monitoring

Remote monitoring is part of home healthcare as patients' conditions can be monitored remotely with devices such as monitoring wearables that can take measurements. One example will be the latest Apple watch that can measure pulse rates and inform users about unregular rhythms detected. The GPS watch manufacturing expert Garmin also sells watches that can track heart rate, blood oxygen saturation and hydration. The trend of these massive multinational firms moving into consumer healthcare demonstrates that the remote monitoring field has more opportunities to be explored. However, although the data collection must pass the clinical trial stage assessed by Food and Drugs Administration, experts still hold doubts regarding data accuracy and safety collected by these wearables since these tech firms' experiences are more in the field of consumer goods rather than professional healthcare equipment development.

Rising demand for healthcare in hospitals

The growth in pulse oximeter market closely ties with that of the inhospital healthcare since hospitals are major clients of medical devices developers. Supply-side factors such as increasing access and availability of hospitals and clinics in the country and surging demand for quality healthcare due to ageing population have led to a steady increase in the hospital admission in the United States. Before the pandemic, the number of yearly hospital admission in the United States increased at a slow and steady pace from 35,562 thousand admissions in 2014 to 36,242 thousand admissions in 2019 (Figure 6). In contrast, the healthcare expenditure in hospitals in the country has been spiralling at a much faster rate at around 5% per year from US\$907,755m in 2014 to US\$1,161,032m in 2019 (Figure 7)., faster than the increase of healthcare cost at 4.2% per year after Affordable Care Act was signed. Hence, it can be inferred that more hospitals are providing for more expensive services that may require medical equipment such as pulse oximeter, benefiting the manufacturers and MedTech companies.

Tailwinds of COVID-19 pandemic in recent two years

During the peak period of the COVID-19 pandemic, hospital are filled with COVID-19 patients, especially when new variants of the virus just appeared. For example, in January in 2022, the omicron-driven surge led to over 145,000 patients hospitalised within one week across the United States and these patients filled about 30% of ICU beds in the nation. For COVID-19 patients with acute symptoms, consistent observation and monitoring of blood oxygen level are needed, so during that period of time the demand for pulse oximeter surges in order to cope with the rising number of hospital admissions. Besides, individuals who are concerned about COVID-19's impacts might also consider purchase pulse oximeter as home healthcare products. These all contribute to the continuing growth of the pulse oximeter market, and as the pandemic persists, the high demand is expected to sustain.

Porter's Five Forces

Competition within industry - Moderate

There are quite a few large businesses that operate in the noninvasive patient monitoring technologies production including Medtronic, General Electric Company, Philips and Edward Science. Masimo's pipeline specialises on and development of pulse oximeters and complementary products while the above competitors might offer a more diverse range of services or products. As one of the main players in the pulse oximeter industry with 51% of market share by revenue, followed by Nellcor under medical device giant Medtronic, Masimo differentiates itself with its superior products with better data accuracy and complimentary products, and it has also reached agreement with competitors including GE and Philips to produce for them since its expertise and quality of product are widely recognised.

Threat of new entrants - Low

The barrier to entry for non-invasive monitoring technology industry is rather high because of dominance of the larger players that have reached agreements with most institutional clients such as hospitals. New entrants would need to have ground-breaking technology that differentiates itself from the current major players to sway the hospitals and clinics to switch, and both ways would require high capital devoted to research and development and establishment of manufacturing facilities.

Threat of substitutes - Low

Pulse oximetry is one of the most common technologies used in and out of hospitals for oxygen saturation monitoring, and it has gained widespread clinical acceptance as a standard patient vital sign measurement tool. The possible alternative might be consumer-grade watches or wearables that have similar functions or conventional pulse oximeters, but Masimo's products are superior in terms of accuracy since its core technology Masimo SET® has a smaller margin of error of 1.5% under different saturation ranges with similar price as conventional ones with a margin of error of around 2% under normal saturation range proven by clinical data. Saturation range can be different for stable and critically ill populations, and the margin of error of pulse oximeter can be affected by this factor, leading to inaccuracies. Masimo resolved the problem by optimizing its complementary products such as sensors and designing specific solutions to cater to groups with special conditions. In comparison, consumer-grade wearables for tracking physical activity showed large variations in accuracy between different devices—with error margins of up to 25% which is a serious discrepancy for professional healthcare. Consumer-grade wearables also introduce problems in terms of data privacy since they can measure a variety of data simultaneously such as locations of the users that might not be needed by professionals, making patients worried about security of their personal data. Thus, it is unlikely for Masimo's products to be substituted by the consumer-grade wearables.

Bargaining power of customers - Moderate

The bargaining power of customer in the United States mainly arises from hospitals as well as individual consumers, and professionals remain the major group of consumers for Masimo's current products. With the competitions between the major companies, if the hospitals decide to switch, there are other options available for them to choose from. The hospitals generally have a sufficient amount of knowledge

Figure 8: Porter's Five Forces



Source: Team Estimates

regarding the performance of the pulse oximeters, so they will prefer the products with affordable price and higher quality. Thus Masimo faces the pressure to consistently improve the products' performances so that it can maintain its product advantage and ensure the price of its products similar to that of competitors.

Bargaining power of suppliers - Low to Moderate

Masimo employs an in-house manufacturing strategy since it is more efficient and cost-effective. Hence the main suppliers for Masimo are contract manufacturers that manufacture certain components such as circuit boards and supplier for raw materials, and Masimo relies on sole source suppliers for digital signal processor chips and analogue-Therefore, Masimo and contract to-digital converter chips. manufacturers have taken action to prevent stoppage or shortage by maintaining safety stock and designing software that can be easily ported to other types of chips. Masimo has also reached agreements that only allows termination upon specified notice at least four months in advance with major suppliers. In the first quarter this year when Masimo was facing shortages of critical components and shipping delay, it managed to contain the issue within Q1 by identifying new vendors and switching to new companies for shipment. Hence the risks of shortage of components happening are low given the prevention measures and ease of switching suppliers as well as their experience in managing similar issues (Figure 8).

Investment Thesis

1. Masimo's acquisition of Sound United seems to be an unrelated move at first glance, but in fact it represents an underappreciated opportunity by the market.


Announcement of Acquisition of Sound United

On 15 February 2022, Masimo announced that it had acquired Sound United, a consumer-focused audio, speaker and headphone business for US\$1.025 billion. Investors were shocked by the decision and on the next day, Masimo's stock price dropped by 37%, wiping out US\$5 billion of its market value. The reasons behind the plunge of the stock price can be summarised as the following two with the former as the main concern: 1) Doubts on strategic directions behind the acquisition since the two industries of Sound United and Masimo are completely unrelated and there are no cost synergies to be derived; 2) There can be loss of profitability since Masimo's gross margin was at 65.8%, significantly higher than that of Sound United. The rationales given by Masimo including integration of technology from both companies and developing hearing aids or enhanced earbuds were considered relatively vague by investors and therefore failed to convince them at that point of time (Figure 9).

Seizing hidden opportunities with a hospital-to-home strategy

While market sentiment has largely been that of confusion with regards to strategic direction, we believe that this is actually a sound acquisition strategy that plays to seizing hidden opportunities in various markets: from the latest earnings call presentation, Masimo has revealed its ambitious strategy behind the unusual move: it is planning to penetrate into consumer-focused businesses. Considering this trend, Masimo's seemingly vague rationales become clearer, implying that it is actually considering developing monitoring wearables and hearing aids by incorporating technology from both

Figure 9: Masimo' s Share Price in Last 12 Months Showing the Drop after Acquisition \$350.00



Source: Yahoo Finance

teams to capitalise on the trend by moving from hospital to home healthcare.

Opportunities in the hearing aids market

The U.S. market for hearing aids has shown a steady growth with a forecast CAGR of 8.46% from US\$3,606m in 2019 to US\$6,368m in 2026 (Figure 10). It is also a good time to enter into this market since recently on 16 August, 2022, FDA passed the regulation for over-the-counter hearing aids to be allowed for consumers with mild and moderate impairments without going through complicated medical examinations. This means hearing aids can be purchased as a consumer-product by consumers directly, which will improve the access to the market and thus presenting new opportunities.


Opportunities in the remote vital measurement market

Monitoring and remote vital measurements segment is another direction that Masimo is looking at. It is a fast-growing industry serving both professionals and consumers of different kinds of demands. For professional cardiac monitoring devices, the market is driven by the growth in medical grade wearables with a CAGR of 29.6% from 2019 to 2026 (Figure 11). The broader wearable markets can be segmented into three sub-markets: 1) the consumer-grade wearables which has the largest market amongst the three with a market size of over US\$80 billion and penetrated by tech companies, but the quality of the data measured by the products is low: examples will be normal smart watches that are able to measure body measures; 2) medical-grade wearables that can provide higher quality data for professional use: many of Masimo's current products including pulse oximeters belong to this market; 3) the clinical-grade wearables for consumers with the clinical data of devices accuracy examined by FDA: the market size is at around US\$8.6 billion, and some of the tech giants' latest products including Apple Watch are within this market. Masimo's shift to consumer product is an attempt to enter the clinical grade consumer wearable markets to capture the opportunities since it is a larger global market compared to the current pulse oximetry market and has a relatively fast growth rate as shown by a CAGR of around 25.2% in next five years (Figure 13). Meanwhile it is less penetrated by large tech companies than the consumer-grade wearable markets. FDA's requirements for highly accurate data also caters to Masimo 'core technology's strength of capturing and storing accurate body measurements while the competitors with less experience in developing professional healthcare monitoring devices can potentially face trouble or costside restraints when trying to ensure their products pass the strict clinical data assessment.

Experienced and innovative management team to lead the change


Other than the strategic direction of the company, investors are have doubts about whether the Masimo has the capability to benefit from this unconventional move. Masimo has been specialising in nonintrusive monitoring as a MedTech firm and it seems to have no experience on acquisitions or ventures into novel fields at all. In fact, Masimo is led by a team with excellent track records on innovation as well as acquisition. The CEO Joe Kiani who is also the founder of Masimo created the core technology Masimo SET® that Masino's main products rely on. The rest of the teams also have years of experiences in the industry. Other than Masimo SET®, Masimo has 11 other technologies registered with different functions, which shows it has

Figure 10: U.S. Hearing Aids Market



Source: Fitch Connect

Figure 11: U.S. Monitoring and Remote Vital measurement Market




Source: Frost & Sullivan

Figure 12: Wearables Market Segments



Source: Frost & Sullivan

Figure 13: Global Clinical-grade Wearables Revenue Forecast



Source: Frost & Sullivan

Figure 14: Masimo's new W1 Watch & SafetyNet Platform for Hospitals



W1 Watch clinical-grade consumer product, uses Masimo SET® as the core technology to ensure its accuracy as their usual products



SafetyNet System to collect data from patients, managed to cut the average length of in-hospital stay by 36% system to collect

Source: Company Website

Figure 15: Tech Firms' Consumer Healthcare Products





Sony Self-Fitting Hearing Aids CRE-C10 (Left) & Apple Watch Series 6 with Blood Oxygen Sensor (Right) Source: Company Websites the ability to bring new products to the market. Its successful acquisition of TNI Medical, a German company that produces ventilation devices using novel technology and accounts for 20% of Masimo's revenue with another non-core product, proves that Masimo has the foresight to acquire companies that are competent in other areas to complement its own product pipeline. Masimo's past attempts to enter into new markets also demonstrate that they are able to expand without too much deviation from the core business: for professional products Masimo explored into telemedicine and integrated platforms such as their SafetyNet Platform that can collect and store data in central system in hospitals and cut the length of stay of patients by 36% during the time when COVID-19 cases surged in number; and for hospital-to-home products, Masimo has already made its attempt by releasing its new clinical-grade prosumer wearable - the W1 watch with Masimo SET® remaining as the core technology behind the product. It will also include a new type of novel measurement called Hydration Index launched to measure fluid intake to target at more specific groups such as athletes and patients (Figure 14). From the records we believe Masimo has the ability to maintain its strong growth in the core business while expanding into new niches.


Precedent cases of cross-industry acquisition


Many investors are also concerned that ventures of a MedTech company into the consumer goods industry are completely unheard of, so it is impossible to prove the acquisition's feasibility. Although it seems uncommon, there are actually some successful cases of similar acquisitions. In 2021, a Swiss-based hearing aid maker and MedTech company Sonova group acquired the consumer division of Sennheiser, a company that produces headphones, to seize growth opportunities in the fast growing consumer market. Upon the completion of the acquisition, the stock price of Sonova increased by around 30%. As aforementioned, some tech firms have also indicated interests in entering the consumer healthcare market. For example, Apple introduced blood oxygen saturation measurement in its Apple Watch Series 4, 5 and 6 while Sony made its attempt by pushing out the Self-Fitting CRE-C10 hearing aids to enter the OTC hearing aids market (Figure 15). With strong market potentials in the markets and a visionary and experienced team, Masimo would be able to follow such cases and take advantage of the new venture.

Looking into more tangible financial benefits that outweigh the cost

Beside the strategic advantages the acquisition might potentially provide in the long-term perspective, Sound United is a steadily growing company with a profit margin around 35% to 36%, above that of the industry average. The consumer audio industry, despite being inflated in 2020 and 2021 recently due to the pandemic and is expecting a drop of 11% in 2022, will resume the usual growth rate of around 3% to 5% soon, and Sound United is expected to follow the trend in the upcoming years. For 2022Q3 there is a slight decline in Sound United's revenue of around 2% compared to that of the same quarter in 2021, but it is already buffered compared to the drop in revenue in the market. By the end of the year Sound United is expected to help Masimo to increase the revenue by around 67%. Masimo has entered into a credit facility for an unsecured term loan of US\$300M and US\$500m in unsecured revolving commitments just for the acquisition. With much higher addition to revenue with lower increase in expenses and Sound United's current annual revenue at Oximetry Market (vs. closest competitors)

Figure 16: MASI's Increasing Share in Pulse





Source: Company Websites and Research

around US\$900m, Sound United can be expected to recover the cost of acquisition solely within three years and pays back the debt within two years.

Ultimately, with the foresight to make a daring strategic direction, Masimo can be expected to benefit more than expected from this acquisition and secure a steady profit-earning position while attempting to diversify its pipelines and expanding its horizons.

2. MASI can leverage on market dominance in continuous monitoring technology to capture opportunity in hospital general wards, contributing to long-term growth and value MASI's entrenched position in the industry:

MASI has steadily increased its foothold within the pulse oximetry industry during the last decade (Figure 16), capturing 51% market share as of the latest period. Even though MASI has proven its superiority in technology front, it took the company more than 20 years to fully gain a leading role in the market. This speaks into the slow change and long product life cycle, usually 10 to 15 years for these devices, of the medical equipment market in general. However, the slow penetration rate of the industry would serve wonders for MASI now as the company will comfort

tably keep and expand its market share.

To solidify and keep its current stance, MASI adopts a customercentric culture in developing and innovating.

Recently, MASI announced that they have once again raised the industry standard for pulse oximetry technology by reducing the margin of error of SET from 3% (previous best clinical deviation) to 1.5%. The improvement, which unconsciously seems minimal, is utmost crucial to measuring oxygen saturation since a healthy human being requires a reading of 95 to 100 on a scale of 100. Therefore, reducing margin of error is undoubtedly a priority, especially for cases of vulnerable patients whose health profile must be determined with little compromise to accuracy.

Alongside with addressing patients-centric issue, MASI also focuses on alleviating pain points for doctors and healthcare practitioners through reducing physical and mental inefficiency. False alarm is one of the top technology hazards according to ECRI for healthcare professions as it creates unnecessary burdens and workloads while desensitizing physicians from future alarms. Therefore, the consequences of false alarm issues will not only take a toll on the physicians' effectiveness but also on the patients' health. Through numerous research, SET is shown to have the best true detection rate and lowest false alarm rate (Figure 17). SET's superior performance has once again alleviated a hazardous problem, which would in turn increase trusts and dependence of practitioners and physicians.

<u>Current issues within hospital general wards imply an underserved</u> <u>market for Masimo:</u>

While it is true that most intensive and critical care beds have implemented continuous monitoring, the same cannot be said for general wards. From the current landscape of general wards response chain (Figure 18), it is found that most countries have already implemented emergency response team ("ERT"), but the monitoring of vital signs is still conducted by spot-checks and discretely by



■ Maismo ■ Medtronic (Nellcor) ■ Others

Source: Company Filings and Presentations; Stifel


Estimates

Figure 18: General Wards Response Chain



Source: JMIR Publications

Figure 19: Continuous Monitoring vs Spotchecks




Source: Team Illustrations

Figure 20: Changing Patients' Case-mix



■ 18-44 years ■ 45-64 years ■ 65 years and over *Source: US CDC - NCHS*

Figure 21: Hospitals' Inefficiencies by Category



Source: Fierce Healthcare

nurses. This poses a major issue since effective response depends on the timeliness of monitoring data. Furthermore, traditional discrete monitoring also brings about 2 major problems: misrepresentation of patient health and nurses' subjectivity bias.

Lack of continuous data will depict a non-clear representation of patients' health since the interval between spot-checks might have already shown signs of deterioration which go unnoticed (Figure 19). Without continuous monitoring, the onset of deterioration will not be captured in a timely and effective manner.

It has recently been researched that nurses tend to bypass the mandatory 5 vital signs monitoring and rely on their clinical judgement more, thus introducing more subjectivity bias during these spot-checks. In last 2 decades, patient's case-mix has become older, sicker, and with less obvious signs (Figure 20). Therefore, without the holistic measurements of all vital signs, major consequences would ensue such as unexpected development of deterioration and health degradation.

The combined issues have previously surfaced and cost all participants greatly. For hospitals, capital inefficiency and subsequent liabilities for patients' death are few of the examples. In 2018, it is estimated that hospitals wasted US\$11 billion on miscommunication, with emergency response and inter-ward transferal amounted to half of that number (Figure 21). For patients, financial burden and longer days in hospitals are the leading concerns. Ultimately, it is the question of life and death of the patients.

Addressable market opportunities for Masimo's long-term growth:


While MASI has penetrated fully critical care beds for continuous monitoring, only 10% of the potential 800,000 general ward beds have implemented MASI continuous monitoring technology (Figure 22). Moreover, the non-penetrated segment holds no competition from other major players but traditional vital signs monitoring as discussed above. This represents an estimated addressable market size of US\$1.5 to 2.5 billion for MASI to capture in the long run.

In summary, MASI's current entrenchment along with its patient/physician-centric approach will prime MASI for capturing new opportunities existed in the general wards, thus contributing to long-term growth and value.

Catalysts

- There is currently an ongoing lawsuit between Apple and Masimo regarding Masimo's new W1 watch which provide similar features as Apple's watch on oxygen saturation measurement. Previously in 2020 Masimo sued Apple for severing its patent on oxygen saturation measurement and stealing trade secrets. Masimo is experienced in patent right lawsuits against larger competitors in the industry such as Nellcor and Royal Philips and have earned a lumpsum of compensation from such lawsuits, so if Masimo continues to win this lawsuit it might shed the company in a positive light as an exemplar of anti-poaching and originality.
- Masimo has submitted 510(k) application for W1 to get the device onto the market faster, and they might hear back from FDA soon before Investor Day in December to announce the feedback,

Figure 22: Continuous Monitoring Landscape in Critical Care vs General Care



Source: Company Presentations

which might lead to full launch of the product. Meanwhile on the Investor Day more details about earnings and clearer strategic directions will be revealed which may clarify doubts for investors and boost the market's confidence.

- According to American Academy of Paediatrics (AAP) and the Children's Hospital Association there can be an alarming surge of respiratory illness among more vulnerable communities, and the organisations are urging Biden's Administration to take action. This might affect government's resources allocation and to address such demand more resources might be devoted to equipping hospitals with necessary devices, leading to rising demand for Masimo's products.
- According to the CEO Joe Kiani, the engineering team from both Masimo and Sound United have been working on new projects together. If the team manages to attain some progress, the announcement of the news might restore investors' confidence in the acquisition.

Financial Analysis

	FY22E	FY23E	FY24E	FY25E	FY26E	FY27E	FY28E
Revenue	2,019	2,400	2,568	2,741	2,931	3,132	3,349
GP	1,083	1,264	1,380	1,502	1,638	1,784	1,943
Margin (%)	53.6	52.7	53.7	54.8	55.9	57.0	58.0
EBIT	214.9	242.2	296.8	358.2	426.4	502.4	586.8
Margin (%)	10.6	10.1	11.6	13.1	14.5	16.0	17.5
Net Income	132.5	154.1	192.5	249.3	303.1	359.3	454.8
Margin (%)	6.6	6.4	7.5	9.1	10.3	11.5	13.6
EPS	2.52	2.93	3.66	4.74	5.77	6.84	8.65
ROE (%)	9.2	9.2	9.9	11.0	11.4	11.5	12.4

In US\$ million, except per share values

Overview

The above table reveals MASI's financial conditions for the next seven years, highlighting our assumptions. We are seeing an improvement in both top-line and bottom-line margins, thus resulting in both EPS accretion and higher ROE. Moreover, we are expecting MASI's capital structure to approach zero debt in the long run, aligning with the company's historical appetite. Most indicators yield positive and favourable trends that are supportive of the overall BUY recommendation.

Revenue growth driven by higher instalment base and new customers, continuing to maintain momentum post-COVID

We broke down MASI revenue into two segments for forecasting purpose: Healthcare operation and non-healthcare operation.

<u>Healthcare</u>: we forecast pulse oximetry market size and MASI market share. Together, we derive MASI revenue for the healthcare segment (Figure 23).

As for pulse oximetry market size, we are seeing higher than current consensus market CAGR of 6.4% for the 2022 – 2028 period. We believe that the market growth rate estimates have not fully considered the on-going penetration of continuous monitoring in general wards. The reason can be point back to our thesis 2 combining with the catalytic COVID event, which pushed hospitals to further realize the importance of accurate and reliable measurements belonging to MASI products. Without these accurate measurements



Figure 23: Healthcare Revenue Assumptions

Source: Team Estimates

in place, many hospitals would have turned patients away and putting their operations at risk.

MASI saw 51% foothold in the market in 2021, and we expect their market share to continue the steam and reach 55% market share in 2028 with a 0.5% equal step-up for the forecast period. Reason to further solidify our assumptions surfaces in the latest quarter announcement: MASI is seeing the strongest nine-month new customer acquisition with installed base to grow 7% this fiscal year. Among the new customers, Denver Health and Nationwide Children's belong to one of the top 10 children's hospital in the United States, thus better entrenching MASI's position in the industry.

<u>Non-healthcare</u>: We forecast consumer audio to grow at a similar rate to the industry and maintain such momentum moving forward due to price-raising initiatives and luxury-stickiness of Sound United's portfolio of brands.

In totality, we are expecting MASI to grow within the high single-digit number, deviating around 6% YOY for our forecast period.

Main operating cost margin seeing a decrease driven by the removal of current market and operational headwinds

We are seeing an improvement in all 3 operating costs margins: COGS, SG&A, and R&D (Figure 24). Primary drivers include reducing effect of current headwinds on COGS and cost and strategic synergy for SG&A and R&D expense.

<u>COGS expense</u>: we broke down by two previously mentioned segments - healthcare and non-healthcare - since the discrepancies is significant. Both segments 2022 COGS margin is assumed to follow management guidance with equal-step improvement throughout the forecast period.

From 2021 to 2022, there was an additional 3% increase in COGS mainly led by FX (1.2%) and operation (1.8%) headwinds. Operation-wise, supply chain inefficiencies manifested in the form of higher freight costs and increased labour costs of some components.

We are expecting higher COGS margin decrease for the healthcare segment to reflect resolving supply chain issues. Moreover, the supply chain issues were at the pinnacle during the first half of 2022, and MASI is expecting an overall improvement, latest by first half of FY23, with active effort in diversifying vendor base. Regarding the consumer audio segment, the brands under Sound United has significant room for raising prices due to its standing in the luxury market and its customer segment being more resistant to economic downturn; thus, stronger ability to raise price as compared to rising costs will result in improving gross margin.

<u>SG&A expense</u>: we are expecting equal-step improvement since MASI can leverage upon 20,000 distribution points of Sound United to deliver its new prosumer products such as W1 and Freedom pulse oximetry watch. Our 2028 SG&A expense will reach 30% of sales due to the aforementioned synergy along with the fact that certain historic quarters have demonstrated similar expectations.

Figure 24: Operating Costs Margin Assumptions (% of revenue)



Source: Team Estimates

<u>R&D expense</u>: After combining the business with Sound United, R&D margin has improved greatly as compared to historic standing. However, based on MASI's vision in developing more products that cater towards patients in a transitory phase and prosumers such as athletes, we are only projecting minimal improvement in R&D margin, starting at 10% of sales to 9.5% of sales in 2028.

Bottom-line improvements leading to EPS accretion and increasing ROE

With both revenue and costs improvement as mentioned above, we are seeing expanding net margin for our forecast period, starting at 6.9% in 2022 and reaching 15.6% in 2028. Thus, assuming constant shares outstanding, EPS will be accretive. ROE will also share the same path (Figure 25).

Cash accumulators in the long-run due to positive operating cash flows, allowing for aggressive investments and share repurchase program

Profitable as MASI was, the company is expected to behave the same moving forward, which will be reflected in our operation cash flow. With steady re-investment in its core assets, cash flow from investing activities also remains stable in our projection. As for MASI's financing activities, big change happens during their debt repayment periods.


Combining the three categories above, we are looking at positive net change YoY for the forecast period, making MASI a cash accumulator (Figure 26). Therefore, we believe the company will have significant room for aggressive investment and share repurchase to enhance EPS (Management in 9M22 has repurchased 3 million shares and there are plans to buyback an extra 5 million shares).

Debt financing is assumed to decrease through times to target a debt-free capital structure with significant cash generated from operations reducing the needs for external financing

For the current fiscal year, MASI increased its debt account mainly to finance the acquisition of Sound United. Its debt-to-equity ratio saw a change from previously 0 to 0.77 in 3Q22. As for the long-term, we believe MASI will be targeting a debt-free capital structure based on the company's historical preference. Therefore, debt-to-equity ratio will naturally decrease (Figure 27) through our forecast period – mainly on the year of debt maturity.

Moreover, since MASI has historically generated positive internal cash flow and continue to remain so during our forecast, we believe the pecking order theory would be applicable, thus justifying the non-necessity for external financing.


With respect to MASI's negative financial covenants for new debt, the company is required to maintain its Net Leverage Ratio ("NLR") below 3.50 and its Interest Coverage Ratio ("ICR") above 3.00. From our model, the worst performance for NLR and ICR is 1.83 and 4.70 respectively, which has shown to not violate any aforementioned restrictive covenants.







Source: Team Estimates

Figure 26: Cash Balance Its Delta Factors (in US\$ million)




Source: Team Estimates





Source: Team Estimates

Figure 28: Football Field Analysis



Source: Team Estimates

Figure 29: ERP Calculation

i igui e 2 7. Liti	calculation	
Region	Revenue %	ERP
North America	57.4%	6.01%
APAC	22.1%	10.35%
EMEA	20.5%	10.89%
MASI		7.97%

Source: Team Estimates

Figure 30: WACC Calculation

0	
Parameters	Figure
Risk-free Rate	3.88%
Beta	0.84
ERP	7.97%
Cost of Equity	10.57%
Target D/Capital	0.00%
WACC	10.57%
Source: Team Estimates	

Figure 31: Terminal Growth Rate

Region	Revenue %	Terminal G
North America	57.4%	2.49%
APAC	22.1%	5.46%
EMEA	20.5%	2.36%
MASI		3.12%

Source: Team Estimates

Valuation

We weighted our DCF valuation of US\$146.34 and blended multiple valuation of US\$156.19 at a weightage of 50:50. Valuation Price Target: **US\$151.27**

DCF Model

A Discounted Cash Flow model (with a 7-year forecast period – from 2022 to 2028) was used to estimate the intrinsic value of MASI's share price.

We modelled revenue based on two segments: healthcare and nonhealthcare. Operating costs margin are assumed to decrease through time due to the removal of current headwinds that MASI is encountering. For further explanation of our assumptions, details are mentioned in the Financial Analysis section above. Overall, we are seeing expanding operating and profit margins from start to finish of the forecast period.

The DCF model was built following guidance from historical performance, annual reports, Q3 earning calls, and industry outlooks. Both the exit multiple method and the Gordon growth method were used (and weighted equally) to obtain a blended target price of US\$146.34 – representing a 5.7% upside from latest closing price.

Weighted Average Cost of Capital (WACC)

The CAPM was used to estimate the Cost of Equity. The Risk-free rate was taken to be the 10Y US Treasury Yield, standing at 3.88%. An Equity Risk Premium of 7.97% was derived by weighing MASI's exposure to three main operating regions (Figure 29). Beta was calculated by regressing MASI's monthly adjusted closing price with the relative index (S&P 500 in our case) for a 5-year span, arriving at a figure of 0.84. Incorporating all these components, we arrive at 10.57% for our Cost of Equity.


Since we believe that MASI will be targeting a debt-free structure in the long-run with details explained in our *Financial Analysis* section, the WACC is thus equalled to our Cost of Equity (Figure 30).


Terminal value

We applied two terminal value methods: Gordon Growth Method and EV/EBITDA exit multiple. We weighted the two approaches 50:50 to arrive at a blended terminal value of US\$16,058 thousand.

For Gordon Growth, the long-term growth rate for each geographical region was derived by averaging out each region's historical real GDP growth rate. Then, weighing by revenue contribution, we arrived at a terminal growth rate of 3.12% (Figure 31). For exit multiple, we chose median EV/EBITDA from our comps-list, which stood at 37.29x.

Upon further analysis, we noticed that the exit multiple method showed a much higher value as compared to the Gordon Growth method. We believe the market overall optimistic for MedTech companies is justifiable given how COVID-19 has pushed the needs for innovation and technological advance within the healthcare space. Moreover, U.S and European MedTech companies saw a steep decline in market capitalization for the first half of 2022, as the market felt the steam of COVID-19 has slowed down and has started to dissipate.





Source: Team Estimates

However, according to EY research, it is shown that the outlook for MedTech companies is bright if they could navigate through 3 main obstacles: innovation, new commercial models, and supply chain transformation. We believe all these obstacles are addressable given how the industry has shown its resilience during COVID period. Moreover, from MASI's own example, effort to create new commercial model along with suppressing supply chain issues are already on the way, thus further demonstrating MASI in specificity and the industry as a whole capability to live up to market expectation, justifying the high trading multiples.

Sensitivity analysis

We deployed sensitivity analysis on 4 variable-pairs (Figure 32): WACC - terminal growth, WACC - exit multiple. COGS (healthcare) -COGS (non-healthcare), SG&A expense – R&D expense. Overall, our extreme-pessimistic figure for each analysis suggests that US\$120.08 is the minimum price that MASI should be trading at, representing a 13.3% downside compared to current price. On the other hand, an optimistic improvement will result in target price ranging from US\$160 to US\$175.

Relative valuation


Since our comps-list has positive earnings along with non-significant capital expenditure expense, we chose EV/FWD EBITDA and P/FWD E multiples to derive our relative valuation for MASI.

We set up two lists of comparable companies - one for MedTech segment and the other for consumer electronics. Afterwards, we weighed the multiples of these two sets based on MASI's revenue mix of healthcare and non-healthcare. Thus, we assume that MASI should be traded with proportionate exposure to both segments – 33.3% for consumer electronics and 66.7% for MedTech. Additionally, it should be noted that consumer electronics are traded with much lower multiples as compared to the MedTech space.

Evaluating MASI's multiples against the comps' median, we noticed that MASI is currently trading at a discount. Market's pessimism over Sound United acquisition is our general comments, which is not justifiable as we have illustrated in thesis 1. Moreover, since we derive our median multiples based on MASI's revenue mix weightage, MASI's current trading multiples imply that the market sees MASI as much more exposed to the consumer electronics segment, which again is not the case based on our long-term revenue contribution forecast.

The weighted median EV/FWD EBITDA came at 30.51x while the weighted median P/FWD E stood at 44.33x. Thus, if MASI is traded at current median, its share price would be US\$161.42 and US\$150.97 respectively.

Figure 33: Risk Matrix



Source: Team Estimates

Investment Risks

Market Risk (MR)

Inflation erodes consumer spending, cutting MASI's audio segment revenue: Since the acquisition of Sound United, MASI has expanded its customer base to include retail consumers. Considering current inflationary periods, consumer spending will decrease and thus has a damaging effect on MASI's non-healthcare segment, which contributes to one-third of the company's total revenue. Moreover, with raw materials price increase, top-line margin of MASI will be compressed due to such happenings.

However, we believe current economic condition will not have tremendous impact on MASI due to its strongly hedged position on both demand and supply fronts. Per supply, the company is keeping enough stocks to weather through the period according to call transcript. Moreover, historically, consumer audio segment's inventory has been kept levelling around one-third of COGS; therefore, we have reasons to believe that MASI is well-positioned to use current inventory to sail through the inflationary period. As for demand side, Sound United's portfolio of premium brands such as Bowers & Wilkins, Marantz, and Denon target high-income customers who are less affected by economic downturns. Were situation to get worse, MASI has plans to raise prices and pass on the inflationary cost to consumers.

Business Risk (BR)

Lower capex from hospitals reduces revenue growth for healthcare segment: There are mixed feedback on the Street about hospitals decreasing capex, thus implying a potential risk for MASI's healthcare revenue segment.

However, we believe the surface of such problem is overstated considering the supply chain issues that companies engaging in medical equipment manufacturing are facing. Therefore, the problem originates on the supple side rather than the demand side per se. Moreover, MASI has continued to see great growth in its shipments and revenue during this fiscal year amid such claim, which signals that the risk is not materialistic in nature. Additionally, MASI has already taken action to expand its supplier base with an effort to alleviate industry-wide supply chain issues.

Strategic Risk (SR)

Lack of co-integration synergy for audio technology: One of the rationales for Sound United acquisition includes MASI's endeavour to leverage on the audio technology and integrate into its new healthcare products. Still, there remains risk of such effort would not be fruitful considering MASI's healthcare product portfolio has very small composition coming from sound-based equipment. Therefore, R&D expense might be an exercise in futility.

However, while we think the above scenario is hard to negate, we believe that the acquisition targeted Sound United's distribution channels more. With more plans to roll out prosumers' devices, tapping on a 20,000 stores channels from Sound United will help improve MASI's SG&A margin, which will help absorb the loss from R&D and thus maintain a stable operating margin.

Disclaimer

This research material has been prepared by NUS Invest. NUS Invest specifically prohibits the redistribution of this material in whole or in part without the written permission of NUS Invest. The research officer(s) primarily responsible for the content of this research material, in whole or in part, certifies that their views are accurately expressed and they will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this research material. Whilst we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee its accuracy or completeness, and you should not act on it without first independently verifying its contents. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. You may wish to seek advice from a financial adviser regarding the suitability of the securities mentioned herein, taking into consideration your investment objectives, financial situation or particular needs, before making a commitment to invest in the securities. This report is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein. The research material should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this research material are subject to change without notice.

© 2022 NUS Investment Society

Appendix:

Pro-Forma Financial Statements

Masimo Corporation									
Fiscal Year Ended 31 Dec									
0					F	orecast Years			
	SD thousands 145.43								
Target Pice	FY19A	FY20A	FY21A	ттм	FY22E	FY23E	FY24E	FY25E	FY26E
Balance Sheet			11210			11202	11242	11202	
Assets									
Current Assets Cash and cash equivalents	567,687	641,447	745,250	219,500	752 422	900 699	993,680	1,276,424	1,467,375
Short-term investments	120,000	041,447	745,250	219,500	753,133	890,688	993,660	1,270,424	1,467,375
Accounts receivable	132,433	141,350	200,765	371,600	331,942	394,530	422,193	450,523	481,824
Inventories	115,871	215,952	201,370	495,400	410,365	497,898	521,009	542,786	566,875
Other current assets	60,071	102,416	91,027	159,100	183,968	218,655	233,986	249,687	267,035
Noncurrent Assets									
Lease receivable, non-current	49.936	57,666	73,688	79.600	79,600	79,600	79,600	79,600	79,600
Deferred costs and other contract assets	16,214	20,076	28,093	37,000	42,783	50,850	54,415	58,067	62,101
Property and equipment, net	219,552	272,511	272,793	372,200	405,528	445,160	481,355	517,327	549,647
Customer relationships, net	-			204,500	204,500	204,500	204,500	204,500	204,500
Acquired technologies, net	-	-	-	163,900	163,900	163,900	163,900	163,900	163,900
Intangible assets, net Trademark	27,251	73,923	72,502	78,200 262,000	78,200 262,000	78,200 262,000	78,200 262,000	78,200 262,000	78,200 262,000
Goodwill	22,350	103,206	100,334	446,300	446,300	446,300	446,300	446,300	446,300
Deferred tax assets	35,972	39,363	52,607	56,500	56,500	56,500	56,500	56,500	56,500
ROU assets	19,137	32,324	30,486	69,800	80,772	96,002	102,734	109,627	117,244
Other non-current assets	9,654	12,318	18,095	40,800	47,177	56,073	60,004	64,030	68,479
Total Assets	1,396,128	1,712,552	1,887,010	3,056,400	3,546,667	3,940,857	4,160,376	4,559,471	4,871,581
Liabilities									
Current Liabilities									
Accounts payable	54,548	64,061	75,627	267,800	205,182	248,949	260,504	271,393	283,438
Accrued compensation	54,705	71,601	70,835	90,400	104,530	124,239	132,950	141,871	151,728
Deferred revenue	25,939	44,935	50,877	77,600	89,729	106,648	114,125	121,783	130,245
Current lease liabilities Other current liabilities	4,653 32,374	5,975 47,264	6,371 64,026	18,500 119,200	16,794 137,831	19,840 163,820	21,187 175,306	22,565 187,069	24,089 200,066
Short-term debt		47,204	-	13,800		270,562	-	153,638	940,900
						2.0,002		,	0.0,000
Noncurrent Liabilities									
Long-term debt		-	-	951,400	1,235,762	965,200	1,118,838	965,200	24,300
Non-current lease liabilities Other non-current liabilities	15,834 40,201	28,373 42,703	26,290 42,739	54,500 210,600	67,178 243,517	79,362 289,433	84,747 309,727	90,262 330,510	96,355 353,473
Total Liabilities	228,254	304,912	336,765	1.803.800	2,100,524	2,268,053	2,217,384	2,284,292	2,204,594
				.,,	_,,	_,			_, ,,
Shareholders' Equity									
Preferred stock	-	-	-	-	-	-	-	-	-
Common stock Treasury stock	54 (526,580)	(638,736)	55 (767,655)	53 (1,169,100)	53 (1,169,100)	53 (1,169,100)	53 (1,169,100)	53 (1,169,100)	53 (1,169,100)
Additional paid-in capital	(526,580) 600,624	703,693	752,513	(1,169,100) 775,047	836,127	908,725	986,412	1,069,313	1,157,973
Accumulated other comprehensive (loss) income	(6,718)		(5,530)	(26,900)	(26,900)	(26,900)	(26,900)	(26,900)	(26,900)
Retained earnings	1,100,494	1,341,215	1,570,862	1,673,500	1,805,963	1,960,026	2,152,526	2,401,814	2,704,960
Total Equity	1,167,874	1,407,640	1,550,245	1,252,600	1,446,144	1,672,804	1,942,992	2,275,180	2,666,987
Total Liabilites and Shareholders' Equity	1,396,128	1,712,552	1,887,010	3,056,400	3,546,667	3,940,857	4,160,376	4,559,471	4,871,581
Income Statement									
								0 740 070	
Total revenue Cost of goods sold	937,837 (308,665)	1,143,744 (400,679)	1,239,153 (430,806)	1,746,353 (786,106)	2,019,311 (936,145)	2,400,060 (1,135,831)	2,568,338 (1,188,551)	2,740,679 (1,238,230)	2,931,096 (1,293,184)
Gross profit	629,172	743,065	808,347	960,247	1,083,166	1,264,229	1,379,787	1,502,449	1,637,912
			-,		,,	, ,			,
Operating expenses:				-					
Selling, general and administrative	(314,661)		(395,291)	(575,691)	(666,373)	(784,020)	(830,429)	(877,017)	(928, 180)
Research and development Litigation awards, settlements/or defense costs	(93,295)	(118,659) 474	(137,234)	(170,434)	(201,931)	(238,006)	(252,553)	(267,216)	(283,339)
Operating income	221,216	255,823	275,822	214,122	214,862	242,204	296,804	358,216	426,392
· · · · · · · · · · · · · · · · · · ·				-					
Non-operating (loss) income	12,950	7,913	(1,442)	14,358	-	-		-	
EBIT	234,166	263,736	274,380	228,480	214,862	242,204	296,804	358,216	426,392
Interest expense				(14,100)	(47,187)	(47,187)	(53,133)	(42,662)	(42,662)
			274,380	214,380	167,675	(47,187) 195,016	243,671	(42,662) 315,553	(42,662) 383,730
	234 166	263 736							505,750
EBT	234,166	263,736	274,380	-	107,075	,	210,011	010,000	
	(37,950)	(23,454)	(44,733)	- (43,533)	(35,212)	(40,953)	(51,171)	(66,266)	(80,583)
EBT		(23,454) 240,282							(80,583) 303,147 11.4%

Cash Flows Statemer

Cash Flows Statement									
Cash flows from operating activities:									
Net income	196,216	240,282	229,647	170,847	132,463	154,063	192,500	249,287	303,147
Adjustments to reconcile net income to net cash provided by operating activitie		,					,	,	
Depreciation and amortization	23,487	29,300	35,620	65,720	52,667	62,576	73,181	80,743	92,504
Stock-based compensation	39,235	42,225	44,624	52,824	61,080	72,597	77,688	82,901	88,660
Loss on disposal of equipment, intangibles and other assets	357	554	479	279	-	-	-	-	-
Provision (benefit) for doubtful accounts	687	82	815	1,415	-	-	-	-	-
(Benefit) provision for amount due from former foreign agent	-	-	-	900	-	-	-	-	-
(Benefit) provision from deferred income taxes	(5,965)	(4,964)	(15,086)	(15,086)			-	-	
Changes in operating assets and liabilities:	(0,000)	(4,004)	(10,000)	(10,000)					
(Increase) decrease in trade accounts receivable	(23,580)	(2,229)	(60,799)	(76,499)	39,658	(62,589)	(27,662)	(28,330)	(31,301)
Increase in inventories	(21,257)	(94,434)	13,493	(69,807)	85,035	(87,533)	(23, 110)	(21,777)	(24,090)
(Increase) decrease in other current assets	(8,536)	(29,984)	6,884	14,184	(24,868)	(34,688)	(15,331)	(15,701)	(17,348)
Increase in lease receivable, net		(29,984) (7,749)		(12,661)	(24,000)	(34,000)	(15,331)	(15,701)	(17,346)
Decrease (increase) in deferred costs and other contract assets	(11,958) 3,308	(2,806)	(16,061)	(37,053)	(5 702)	(8,067)	(3,565)	(3.651)	(4,034)
			(8,053)		(5,783)				
(Increase) decrease in other non-current assets	(226)	(1,320)	57	(22,243)	(6,377)	(8,895)	(3,931)	(4,026)	(4,449)
Increase (decrease) in accounts payable	9,934	7,637	10,988	84,888	(62,618)	43,767	11,555	10,888	12,045
Increase (decrease) in accrued compensation	5,338	15,544	47	(5,553)	14,130	19,709	8,711	8,921	9,857
Increase (decrease) in deferred revenue and other contract-related liabilities	7,739	10,871	7,110	25,410	12,129	16,919	7,478	7,658	8,461
Increase (decrease) in income taxes payable	4,079	(1,301)	6,409	(491)					
Increase in accrued liabilities	746	<mark>9,391</mark>	7,793	(14,707)					
Increase (decrease) in other current liabilities					18,631	25,989	11,486	11,763	12,997
Increase (decrease) in other non-current liabilities	2,038	<mark>(136)</mark>	787	(28,713)	32,917	45,916	20,293	20,783	22,963
Decrease (increase) in ROU assets					(10,972)	(15,230)	(6,731)	(6,894)	(7,617)
Increase (decrease) in lease liabilities					10,972	15,230	6,731	6,894	7,617
Net cash provided by operating activities	221,642	210,963	264,754	133,654	349,066	239,764	329,291	399,459	469,413
Cash flows from investing activities:									
Maturities of short-term investments	160,000	120,000		- 11					
Purchases of short-term investments	(280,000)	-	-	-		-	-	-	-
Purchases of property and equipment	(68,375)	(72,549)	(25,503)	(40,803)	(85,995)	(102,209)	(109,375)	(116,715)	(124,824)
Increase in intangible assets	(4,117)	(7,408)	(9,426)	(15, 126)	(,,	(,	(,,	(,	(
Business combinations, net of cash acquired	-	(112,706)	-	(985,000)					
Deposit to acquire noncontrolling interest		(3,374)		(000,000)					
(Purchases of) proceeds from strategic investments	(5,189)	(6,750)	(2,600)	_					
Business acquisition, net of cash acquired	(0,100)	(0,700)	(2,000)						
Net cash used in investing activities	(197,681)	(82,787)	(37,529)	(1,040,929)	(85,995)	(102,209)	(109,375)	(116,715)	(124,824)
And Brown from Brown have a the block									
Cash flows from financing activities:				4 050 000	070 500		450.000		
Borrowings under line of credit				1,050,600	270,562		153,638	-	
Repayments on line of credit				(96,300)		-	(270,562)		(153,638)
Debt issuance costs	-			(9,300)					
Proceeds from issuance of common stock	28,339	58,424	23,241	11,141					
Repurchases of common stock	(37,555)	(110,540)	(128,917)	(401,417)	-		-	-	
Dividends							-		
Payroll tax withholdings on behalf of employees for stock options	(123)	(2,191)	(16,728)	(25,428)					
Net cash provided by (used in) financing activities	(9,339)	(54,307)	(122,404)	529,296	270,562	• .	(116,924)		(153,638)
Effect of foreign currency exchange rates on cash	812	3,060	(1,448)	(53,848)	-	-	-	-	
	15,434	76,929	103,373	(431,827)	533,633	137,555	102,992	282,745	190,951
Net increase in cash, cash equivalents and restricted cash	10,404	,		1					
Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period	552,641	568,075	645,004	662,800	219,500	753,133	890,688	993,680	1,276,424

Financial Projections

Financial Projections									
Scenario 2 T Income Projections	FY19A	FY20A	FY21A	TTM	FY22E	FY23E	FY24E	FY25E	FY26E
Revenue	937,837	1,143,744	1,239,153	1,746,353	2,019,311	2,400,060	2,568,338	2,740,679	2,931,096
<u>Revenue Build:</u> Healthcare - Puise Oximetry	937,837	1,143,744	1,239,153		1,344,311	1,452,244	1,583,360	1,726,162	1,881,677
Market size Market growth rate	1,953,827 7.0%	2,287,488 17.1%	2,429,712 6.2%		2,585,213 6.4%	2,766,178 7.0%	2,987,473 8.0%	3,226,470 8.0%	3,484,588 8.0%
Bull case Base case				E	7.0% 6.4%	7.7% 7.0%	8.8% 8.0%	8.8% 8.0%	8.8% 8.0%
Bear case MASI market share	48%	50%	51%		52.0%	52.5%	53.0%	5.8%	5.8%
Bull case Base case	4070	30%	51%	-	52.0% 52.0%	53.0% 52.5%	54.0% 53.0%	55.0% 53.5%	56.0% 54.0%
Bear case					52.0%	52.0%	52.0%	52.0%	52.0%
Non-healthcare - Consumer Audio Market size		43,164,200	55,894,850		675,000 49,329,630	947,816 51,950,480	984,978 53,987,320	1,014,517 55,606,400	1,049,419 57,519,380
Market growth rate Bull case			29.5%		-11.7% 708,750	5.3% 1,042,598	3.9% 1,083,476	3.0% 1,115,969	3.4% 1,154,361
Base case Bear case					675,000 641,250	947,816 853,035	984,978 886,480	1,014,517 913,066	1,049,419 944,477
Cost build: COGS % of revenue	(308,665) (32.9)%	(400,679) (35.0)%	(430,806) (34.8)%	(786,106) (45.0)%	(936,145) (46.4)%	(1,135,831) (47.3)%	(1,188,551) (46.3)%	(1,238,230) (45.2)%	(1,293,184) (44.1)%
Margin contribution (% of total revenue) Healthcare - Pulse Oximetry Nor-healthcare - Consumer Audio					66.6% 33.4%	60.5% 39.5%	61.6% 38.4%	63.0% 37.0%	64.2% 35.8%
Healthcare - Pulse Oximetry Bull case Base case					(37.0)% (33.3)% (37.0)%	(36.3)% (32.7)% (36.3)%	(35.7)% (32.1)% (35.7)%	(35.0)% (31.5)% (35.0)%	(34.3)% (30.9)% (34.3)%
Bear case					(40.7)%	(40.0)%	(39.2)%	(38.5)%	(37.8)%
Non-healthcare - Consumer Audio Bull case Base case					(65.0)% (58.5)% (65.0)%	(64.2)% (57.8)% (64.2)%	(63.3)% (57.0)% (63.3)%	(62.5)% (56.3)% (62.5)%	(61.7)% (55.5)% (61.7)%
Bear case					(71.5)%	(70.6)%	(69.7)%	(68.8)%	(67.8)%
SG&A % of revenue Bull case	(314,661) (33.6)%	(369,057) (32.3)%	(395,291) (31.9)%	(575,691) (33.0)%	(666,373) (33.0)% (29.7)%	(784,020) (32.7)% (29.4)%	(830,429) (32.3)% (29.1)%	(877,017) (32.0)% (28.8)%	(928,180) (31.7)% (28.5)%
bul case Base case Bear case					(29.7)% (33.0)% (36.3)%	(29.4)% (32.7)% (35.9)%	(32.3)% (35.6)%	(28.8)% (32.0)% (35.2)%	(28.5)% (31.7)% (34.8)%
R&D	(93,295)	(118,659)	(137,234)	(170,434)	(201,931)	(238,006)	(252,553)	(267,216)	(283,339)
% of revenue Bul case Base case	(9.9)%	(10.4)%	(11.1)%	(9.8)%	(10.0)% (9.0)% (10.0)%	(9.9)% (8.9)% (9.9)%	(9.8)% (8.9)% (9.8)%	(9.8)% (8.8)% (9.8)%	(9.7)% (8.7)% (9.7)%
Bear case					(11.0)%	(10.9)%	(10.8)%	(10.7)%	(10.6)%
EBT Incometax % of EBT	234,166 (37,950) (16.2)%	263,736 (23,454) (8.9)%	274,380 (44,733) (16.3)%	214,380 (43,533) (20.3)%	167,675 (35,212) 21.0%	195,016 (40,953) 21.0%	243,671 (51,171) 21.0%	315,553 (66,266) 21.0%	383,730 (80,583) 21.0%
/6 U EDI	(10.2)%	(0.3) %	(10.3) %	(20.3) %	21.0%	21.0%	21.0%	21.0%	21.0%
6		40.005			21.0%	21.0%	21.0%	21.0%	21.0%
Stock-based compensations % of revenue Bull case	39,235 4.2%	42,225 3.7%	44,624 3.6%	52,824 3.0%	61,080 3.0% 2.7%	72,597 3.0% 2.7%	77,688 3.0% 2.7%	82,901 3.0% 2.7%	88,660 3.0% 2.7%
Base case Bear case					3.0% 3.3%	3.0% 3.3%	3.0% 3.3%	3.0% 3.3%	3.0% 3.3%
Working Capital Asusmptions									
Accounts receivable Days' receivable	132,433 47.10	141,350 43.69	200,765 50.39	371,600 59.81	331,942 60.00	394,530 60.00	422,193 60.00	450,523 60.00	481,824 60.00
Bull case Base case Bear case					60.00 60.00 60.00	60.00 60.00 60.00	60.00 60.00 60.00	60.00 60.00 60.00	60.00 60.00 60.00
Inventories	115,871	215,952	201,370	495,400	410,365	497,898	521,009	542,786	566,875
Days' inventory Bull case Decement	124.52	151.14	176.79	161.76	160.00 160.00 160.00	160.00 160.00 160.00	160.00 160.00 160.00	160.00 160.00 160.00	160.00 160.00 160.00
Base case Bear case					160.00	160.00	160.00	160.00	160.00
Accounts payable Days' payable	54,548 56.13	64,061 54.02	75,627 59.18	267,800 79.73	205,182 80.00	248,949 80.00	260,504 80.00	271,393 80.00	283,438 80.00
Bull case Base case Bear case					80.00 80.00 80.00	80.00 80.00 80.00	80.00 80.00 80.00	80.00 80.00 80.00	80.00 80.00 80.00
Other assets/liabilities						00.00			
Other current assets % of revenue	60,071 6.4%	102,416 9.0%	91,027 7.3%	159,100 9.1%	183,968 9.1%	218,655 9.1%	233,986 9.1%	249,687 9.1%	267,035 9.1%
Deferred costs and other contract assets	16,214	20,076	28,093	37,000	42,783	50,850	54,415	58,067	62,101
% of revenue	1.7% 9,654	1.8% 12,318	2.3%	2.1%	2.1% 47,177	2.1% 56,073	2.1%	2.1% 64,030	2.1% 68,479
Other non-current assets % of revenue	1.0%	1.1%	18,095 1.5%	2.3%	2.3%	2.3%	2.3%	2.3%	2.3%
Accrued compensation % of revenue	54,705 5.8%	71,601 6.3%	70,835 5.7%	90,400 5.2%	104,530 5.2%	124,239 5.2%	132,950 5.2%	141,871 5.2%	151,728 5.2%
Deferred revenue % of revenue	25,939 2.8%	44,935 3.9%	50,877 4.1%	77,600 4.4%	89,729 4.4%	106,648 4.4%	114,125 4.4%	121,783 4.4%	130,245 4.4%
Other current liabilities % of revenue	32,374 3.5%	47,264 4.1%	64,026 5.2%	119,200 6.8%	137,831 6.8%	163,820 6.8%	175,306 6.8%	187,069 6.8%	200,066 6.8%
Other non-current liabilities % of revenue	40,201 4.3%	42,703 3.7%	42,739 3.4%	210,600 12.1%	243,517 12.1%	289,433 12.1%	309,727 12.1%	330,510 12.1%	353,473 12.1%
Operating Lease ROU Assets % of revenue	19,137 2.0%	32,324 2.8%	30,486 2.5%	69,800 4.0%	80,772 4.0%	96,002 4.0%	102,734 4.0%	109,627 4.0%	117,244 4.0%
Current Portion of Operating Lease Liabilities Noncurrent Portion of Operating Lease Liabilities Total Lease InfoInternet	4,653 15,834	5,975 28,373	6,371 26,290	18,500 54,500	16,794 67,178	19,840 79,362	21,187 84,747	22,565 90,262	24,089 96,355
Total lease liabilities Change in ROU assets	20,487	34,348 13,187	32,661 (1,838)	73,000 39,314	83,972 10,972	99,202 15,230	105,934 6,731	6,894	120,444 7,617
% current	23%	13,861	(1,687)	40,339	10,972	15,230	6,731	6,894	7,617
% current % noncurrent	23% 77%	17% 83%	20% 80%	25% 75%	20.0% 80.0%	20.0% 80.0%	20.0% 80.0%	20.0% 80.0%	20.0% 80.0%

Scenario PPE Summary			2	FY19A	FY20A	FY21A	TTM	FY22E	FY23E	FY24E	FY25E	FY26E
Revenue PPE, net				937,837 219,552	1,143,744 272,511	1,239,153 272,793	1,746,353 372,200	2,019,311 405,528	2,400,060 445,160	2,568,338 481,355	2,740,679 517,327	2,931,096 549,647
Cost allocation Buildings and buildin Computer equipment	g improvements t and software	As	ssumed useful life 30 7 3	101,731 19,650 836	122,310 24,693 1.024	142,132 32,450 949	150,000 41,600 10,400	184,398 54,499	225,281 69,831 12,282	269,032 86,237 13,376	315,718 103,744 14,543	365,647 122,468
Demonstration units Furniture and office e Leasehold improvem Machinery, equipme	nents		5 10 7	11,049 15,921 74,210	13,567 19,295 90,843	949 14,200 21,894 103,451	17,800 30,900 140,000	11,260 19,520 39,499 165,798	21,564 49,720 196,461	23,752 60,658 229,274	26,086 72,329 264,288	15,791 28,582 84,812 301,735
Transportation, vehic Land CIP	cles and other		10	29,934 40,216 39,107	33,175 57,151 44,589	33,082 57,027 25,109	32,700 86,800 45,900	34,420 86,800 45,900	36,464 86,800 45,900	38,652 86,800 45,900	40,986 86,800 45,900	43,482 86,800 45,900
PPE, at cost Beginning AD Depreciation				332,654	406,647	430,294	556,100	642,095 (183,900) (52,667)	744,304 (236,567) (62,576)	853,679 (299,143) (73,181)	970,394 (372,324) (80,743)	1,095,218 (453,067) (92,504)
Ending AD Capex				(113,102) (68,375)	(134,136)	(157,501) (25,503)	(183,900)	(236,567)	(299,143)	(372,324)	(453,067)	(545,571)
% of revenue Buildings and buildin				(7.3)% 13,282	(6.3)% 20,579	(2.1)%	(2.3)%	(4.3)%	(4.3)%	(4.3)%	(4.3)%	(4.3)% (49,930)
Computer equipment Demonstration units Furniture and office e Leasehold improvem	equipment			3,068 366 590 (507)	5,043 188 2,518 3,374	7,757 (75) 633 2,599	9,150 9,451 3,600 9,006	(12,899) (860) (1,720) (8,599)	(15,331) (1,022) (2,044) (10,221)	(16,406) (1,094) (2,188) (10,938)	(17,507) (1,167) (2,334) (11,671)	(18,724) (1,248) (2,496) (12,482)
Machinery, equipmer Transportation, vehic Land	ent and tooling			5,473 4,379 16,454	16,633 3,241 16,935	12,608 (93) (124)	36,549 (382) 29,773	(25,798) (1,720)	(30,663) (2,044)	(32,813) (2,188)	(35,014) (2,334)	(37,447) (2,496)
CIP Total net additions				25,787 68,892	5,482 73,993	(19,480) 23,647	20,791 125,806	(85,995)	(102,209)	(109,375)	(116,715)	(124,824)
Buildings and buildin Computer equipment Demonstration units	ig improvements it and software			19.3% 4.5% 0.5%	27.8% 6.8% 0.3%	83.8% 32.8% -0.3%	6.3% 7.3% 7.5%	40.00% 15.00% 1.00%	40.00% 15.00% 1.00%	40.00% 15.00% 1.00%	40.00% 15.00% 1.00%	40.00% 15.00% 1.00%
Furniture and office e Leasehold improvem Machinery, equipme Transportation, vehic	nents Int and tooling			0.9% -0.7% 7.9% 6.4%	3.4% 4.6% 22.5% 4.4%	2.7% 11.0% 53.3% -0.4%	2.9% 7.2% 29.1% -0.3%	2.00% 10.00% 30.00% 2.00%	2.00% 10.00% 30.00% 2.00%	2.00% 10.00% 30.00% 2.00%	2.00% 10.00% 30.00% 2.00%	2.00% 10.00% 30.00% 2.00%
Land CIP				23.9% 37.4%	22.9% 7.4%	-0.5% -82.4%	23.7% 16.5%	-	-	-	-	-
Building and build Useful life	ding improvements	5		30								
Opening Balance Additions Depreciation								150,000 34,398 (6,147)	178,251 40,884 (7,509)	211,625 43,750 (8,968)	246,408 46,686 (10,524)	282,570 49,930 (12,188)
Net Balance TTM FY22E	150,000 34,398	30 30	Final year FY52E FY52E				(5,000) (1,147)	178,251 (5,000) (1,147)	211,625 (5,000) (1,147)	246,408 (5,000) (1,147)	282,570 (5,000) (1,147)	320,311 (5,000) (1,147)
FY23E FY24E FY25E	40,884 43,750 46,686	30 30 30	FY53E FY54E FY55E				(1,147) (1,363) (1,458) (1,556)	(1,147) - - -	(1,363)	(1,147) (1,363) (1,458)	(1,147) (1,363) (1,458) (1,556)	(1,147) (1,363) (1,458) (1,556)
FY26E FY27E FY28E	49,930 53,351 57,044	30 30 30	FY56E FY57E FY58E				(1,664) (1,778) (1,901)	-	-	-	-	(1,664)
Computer equipm	nent and software							(6,147)	(7,509)	(8,968)	(10,524)	(12,188)
Useful life Opening Balance Additions				7				41,600 12,899	46,714 15,331	52,069 16,406	56,156 17,507	58,843 18,724
Depreciation Net Balance			Final year					(7,786) 46,714	(9,976) 52,069	(12,320) 56,156	(14,821) 58,843	(17,495) 60,071
TTM FY22E FY23E FY24E	41,600 12,899 15,331 16,406	7 7 7 7	FY28E FY29E FY30E FY31E				(5,943) (1,843) (2,190) (2,344)	(5,943) (1,843) -	(5,943) (1,843) (2,190)	(5,943) (1,843) (2,190) (2,344)	(5,943) (1,843) (2,190) (2,344)	(5,943) (1,843) (2,190) (2,344)
FY25E FY26E FY27E	17,507 18,724 20,006	, 7 7 7	FY32E FY33E FY34E				(2,501) (2,675) (2,858)	-			(2,501)	(2,501) (2,675)
FY28E Depreciation Demonstration un	21,392	7	FY35E				(3,056)	(7,786)	- (9,976)	(12,320)	- (14,821)	(17,495)
Useful life	ino -			3								
Opening Balance Additions Depreciation Net Balance								10,400 860 (3,753) 7,507	7,507 1,022 (4,094) 4,435	4,435 1,094 (4,459) 1,070	1,070 1,167 (1,094) 1,143	1,143 1,248 (1,170) 1,221
TTM FY22E	10,400 860	3	Final year FY24E FY25E				(3,467) (287)	(3,467) (287)	(3,467) (287)	(3,467) (287)	:	-
FY23E FY24E FY25E FY26E	1,022 1,094 1,167 1,248	3 3 3 3	FY26E FY27E FY28E FY29E				(341) (365) (389) (416)	-	(341)	(341) (365) -	(341) (365) (389)	- (365) (389) (416)
FY27E FY27E FY28E Depreciation	1,248 1,334 1,426	3 3 3	FY30E FY31E				(416) (445) (475)	(3,753)	(4,094)	(4,459)	- - (1,094)	(416) - - (1,170)
Furniture and offic	ce equipment			5								
Opening Balance Additions								17,800 1,720	15,616 2,044	13,347 2,188	10,784 2,334	7,902 2,496
Depreciation Net Balance TTM	17,800	5	Final year FY26E				(3,560)	(3,904) 15,616 (3,560)	(4,313) 13,347 (3,560)	(4,750) 10,784 (3,560)	(5,217) 7,902 (3,560)	(5,716) 4,682 (3,560)
FY22E FY23E FY24E	1,720 2,044 2,188	5 5 5	FY27E FY28E FY29E				(344) (409) (438)	(344)	(344) (409)	(344) (409) (438)	(344) (409) (438)	(344) (409) (438)
FY25E FY26E FY27E FY28E	2,334 2,496 2,668 2,852	5 5 5 5	FY30E FY31E FY32E FY33E				(467) (499) (534) (570)	-	-	-	(467) - -	(467) (499) -
Depreciation		-						(3,904)	(4,313)	(4,750)	(5,217)	(5,716)
Useful life Opening Balance				10				30,900	35,550	40,798	45,670	50,109
Additions Depreciation Net Balance								8,599 (3,950) 35,550	10,221 (4,972) 40,798	10,938 (6,066) 45,670	11,671 (7,233) 50,109	12,482 (8,481) 54,110
TTM FY22E FY23E	30,900 8,599 10,221	10 10 10	Final year FY31E FY32E FY33E				(3,090) (860) (1,022)	(3,090) (860)	(3,090) (860) (1,022)	(3,090) (860) (1,022)	(3,090) (860) (1,022)	(3,090) (860) (1,022)
FY24E FY25E FY26E	10,938 11,671 12,482	10 10 10	FY34E FY35E FY36E				(1,094) (1,167) (1,248)		-	(1,094)	(1,094) (1,167)	(1,022) (1,094) (1,167) (1,248)
FY27E FY28E Depreciation	13,338 14,261	10 10	FY37E FY38E				(1,334) (1,426)	- - (3,950)	- - (4,972)	(6,066)	- (7,233)	(8,481)
				I								

FY19A

FY20A

FY21A

Sci

EY26E

EV2

EY25E

Machinery, equipm	nent and tooling								
Useful life				7					
Opening Balance Additions Depreciation Net Balance			Final year		140,000 25,798 (23,685) 142,113	142,113 30,663 (28,066) 144,710	144,710 32,813 (32,753) 144,769	144,769 35,014 (37,755) 142,028	142,028 37,447 (43,105) 136,370
TTM FY22E FY23E FY24E FY25E FY26E FY27E FY28E	140,000 25,798 30,663 32,813 35,014 37,447 40,013 42,783	7 7 7 7 7 7 7 7	FY28E FY29E FY30E FY31E FY32E FY32E FY34E FY35E	(20,000) (3,865) (4,869) (5,002) (5,500) (5,716) (5,716)	(20,000) (3,685) - - - - - -	(20,000) (3,685) (4,380) - - - - - - - -	(20,000) (3,685) (4,380) (4,688) - - -	(20,000) (3,685) (4,380) (4,688) (5,002) - -	(20,000) (3,685) (4,380) (4,688) (5,002) (5,350) -
Depreciation					(23,685)	(28,066)	(32,753)	(37,755)	(43,105)
Transportations, v	whicle and others								
Useful life Opening Balance Additions Depreciation Net Balance			Finel year		32,700 1,720 (3,442) 30,978	30,978 2,044 (3,646) 29,376	29,376 2,188 (3,865) 27,698	27,698 2,334 (4,099) 25,934	25,934 2,496 (4,348) 24,082
TTM FY22E FY23E FY24E FY26E FY26E FY27E FY28E	32,700 1,720 2,044 2,188 2,334 2,496 2,668 2,668 2,852	10 10 10 10 10 10 10	Final year FY31E FY32E FY33E FY34E FY35E FY36E FY37E FY38E	(3,270) (172) (204) (219) (233) (235) (259) (267) (267) (267) (267) (267) (267) (267)	(3,270) (172) - - - - - -	(3,270) (172) (204) - - - - -	(3,270) (172) (204) (219) - - - -	(3,270) (172) (204) (219) (233) - - - -	(3,270) (172) (204) (219) (233) (250) -
Depreciation					(3,442)	(3,646)	(3,865)	(4,099)	(4,348)

Debt Asharda				FY19A	FY20A	FY21A	TTM	FY22E	FY23E	FY24E	FY25E	FY26E
Debt Schedule												
Short-term debt							13,800		270,562		153,638	940,900
Long-term debt				-			951,400	1,235,762	965,200	1,118,838	965,200	24,300
Total Debt				-			965,200	1,235,762	1,235,762	1,118,838	1,118,838	965,200
Cash BoP				552,641	568,075	645,004	662,800	219,500	753,133	890,688	993,680	1,276,424
Cash Flow from Operations/Investing								263,071	137,555	219,916	282,745	344,589
(-) Mandatory Debt Amortization										(270,562)		(153,638)
(-) Minimum Cash Balance			40.0%					(753, 133)	(883,874)	(993,680)	(1,061,803)	(1,134,355)
Cash Surplus/Shortfall								(270,562)		(153,638)		
D				898,063	4 6 4 6 7 6 4		4 400 750	4 000 000	0.000.005	0.404.400	0.054.500	0.005.000
Revenue % revenue				61.54%	1,040,791 54,58%	1,191,449 54,14%	1,492,753 44,40%	1,882,832	2,209,685	2,484,199	2,654,509	2,835,888
76 revenue				61.3476	34.36%	34.14%	44.40%					
Required Fundraise		Debt Ratio	100%					270,562		153,638		
Debt Raised								270,562		153,638		
Equity Raised												
Total Debt Beginning Balance					-			965,200	1,235,762	1,235,762	1,118,838	1,118,838
(+) Borrowings								270,562		153,638	-	-
(-) Repayments										(270,562)		(153,638)
Ending Balance							965,200	1,235,762	1,235,762	1,118,838	1,118,838	965,200
Repayments	Principal	Interest Rate	Maturity									
Term Ioan	280,300	3.870%	FY27E					-	-	-	-	
Revolver	660,600	3.870%	FY27E					-		-	-	-
Japanese loans	24,300	1.250%	FY30E					-				-
FY22E	270,562	3.870%	FY24E							270,562		
FY23E		3.870%	FY25E									-
FY24E	153,638	3.870%	FY26E									153,638
FY25E	-	3.870%	FY27E FY28E									-
FY26E FY27E	279,301	3.870%	FY29E									
FY28E	279,301	3.870%	FY30E									
Total Repayments		3.870%	TIGOL							270,562		153,638
												100,000
Interest	Principal	Interest Rate	Maturity									
FY22A	280,300	3.870%	FY27E					(10,848)	(10,848)	(10,848)	(10,848)	(10,848)
FY22A	660,600	3.870%	FY27E					(25,565)	(25,565)	(25,565)	(25,565)	(25,565)
FY20A	24,300	1.250%	FY30E					(304)	(304)	(304)	(304)	(304)
FY22E	270,562	3.870%	FY24E					(10,471)	(10,471)	(10,471)		
FY23E	-	3.870%	FY25E									
FY24E	153,638	3.870%	FY26E							(5,946)	(5,946)	(5,946)
FY25E	-	3.870%	FY27E									
FY26E	-	3.870%	FY28E									
FY27E FY28E	279,301	3.870% 3.870%	FY29E FY30E									
Total Interest		3.870%	FT30E					(47,187)	(47,187)	(53,133)	(42,662)	(42,662)
								(41,107)	(41,107)	(00,100)	(42,002)	(42,002)
Equity schdule												
Beginning Retained Earnings				931,073	1,100,494	1,341,215	1,570,862	1,673,500	1,805,963	1,960,026	2,152,526	2,401,814
(+) Net Income				196,216	240,282	229,647	170,847	132,463	154,063	192,500	249,287	303,147
(-) Dividends												
Ending Retained Earnings				1,100,494	1,341,215	1,570,862	1,673,500	1,805,963	1,960,026	2,152,526	2,401,814	2,704,960
Weighted Average Shares Outstanding (the Basic	iousands)			53,434	54,700	55,166	52,565					
Diluted				53,434	58,037	55,166	56,400					
Disto				01,100	00,001	01,002	00,100					
Dividends Declared per Common Share C	Outstanding											
	-											
Dividends Per Share							-		-		-	-
Common Shares (Basic)				53,434	54,700	55,166	52,565	52,565	52,565	52,565	52,565	52,565
Earnings Per Share				3.67	4.39	4.16	3.25	2.52	2.93	3.66	4.74	5.77
Payout Ratio				0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Production APIA						200.000	350 546	PRE 0.17	000.45-	000 805		1 000 0.7
Beginning APIC				533,164	600,624	703,693	752,513	775,047	836,127	908,725	986,412	1,069,313
(+) Share-based compensation expense (+) New Equity Electronic								61,080	72,597	77,688	82,901	88,660
(+) New Equity Financing (+) Reissuance												
(+) Reissuance (-) Treasury Buybacks												
Ending APIC				600,624	703,693	752,513	775,047	836,127	908,725	986,412	1,069,313	1,157,973
					,			,-81	,-20		.,,	.,,
Beginning Treasury				(489,026)	(526,580)	(638,736)	(767,655)	(1,169,100)	(1,169,100)	(1,169,100)	(1,169,100)	(1,169,100)
(+) Buybacks								-	-	-	-	-
(-) Reissuance												-
Ending Treasury				(526,580)	(638,736)	(767,655)	(1,169,100)	(1,169,100)	(1,169,100)	(1,169,100)	(1,169,100)	(1,169,100)

Valuation

Cost of equity	
Rf	3.88%
ERP	7.97%
Beta	0.84
Ке	10.57%

Cost of debt	
Weighted average IR	3.80%
Tax rate	21%
After-tax Kd	3.01%

WACC	
	Based on MV
Target D/Capital	0.00%
Target E/Capital	100.00%
WACC	10.57%

Principal	Weighted	Interest Rate
280,300	29.0%	3.870%
660,600	68.4%	3.870%
24,300	2.5%	1.250%

1,001,101		2110			-,,			
8 505 881					7 274 913			
		Mark	ket Value					
-	13,854	87,478	186,417	238,312	296,305	359,101	431,556	13,681,30
	226,698	87,478	186,417	238,312	296,305	359,101	431,556	13,681,30
	(85,995)	(102,209)	(109,375)	(116,715)	(124,824)	(133,377)	(142,611)	
	179.633	202 491	248 140	299 482	356 480	420 014	490,606	
	267,529	304,780	369,985	438,959	518,897	603,554	701,018	
	0.00	1.00	1.00	1.00	1.00	1.00	1.00	
12/00/2022		12/3//2023						12/01/201
Entry 12/09/2022	2022	2023 12/31/2023	2024 12/31/2024	2025	2026 12/31/2026	2027	2028 12/31/2028	E: 12/31/202
	13,001,307							
50%								
Weight								
r both terminal methods								
30.51								
10.6%								
	3 3 1% 12/9/2022 12/31/2022 138 49 52,530 24 30 51 both terminal methods Weight 50% 50% Entry 12/09/2022	3.1% 12/3/2022 12/3/2022 138.49 52,530.24 30.51 *both terminal methods Weight Terminal Value 50% 5.976,298 50% 21.386,316 13.681,307 Entry 2022 12/09/2022 12/31/2022 12/09/2022 12/31/2022 0.06 267,529 179,633 52,667 232,300 80.393 (85.995) 226,698 - 13,854 8,505,881 213,630 (1,033,200) 13,854	3.1% 12/9/2022 12/31/20/2 138.49 52,530.24 30.51 "both terminal methods Weight Terminal Value 50% 5.976,298 50% 21.386.316 13,681,307 13,681,307 Entry 2022 2023 12/09/2022 12/31/2022 12/09/2022 12/31/2022 12/09/2022 12/31/2022 12/09/2022 12/31/2022 267,529 304,780 267,529 304,780 179,633 202,491 52,667 62,576 232,300 265,068 80,393 (75,381) (65,995) (102,209) 226,688 87,478 - 13,854 87,478 - 13,854 87,478 6,505,881 Mark 219,500 (10,38,200) Less	3.1% 12/9/2022 1231/2022 138.49 52,530.24 30.51 *both terminal methods	3.1% 12/31/2022 12/31/2022 138.49 52,530.24 30.51 'both terminal methods 0.06 50% 50% 21.386.316 13.681.307 12/31/2023 12/09/2022 12/09/2022 12/31/2023 12/09/2022 12/31/2024 12/31/2024 12/09/2022 12/31/2024 12/31/2024 12/09/2022 12/31/2024 12/31/2024 12/09/2022 12/31/2024 12/31/2024 0.06 1.00 1.00 267,529 304,780 369,985 438,959 179,633 202,491 248,140 299,482 52,667 62,576 73,181 80,743 232,300 285,088 321,320 380,225 80.393 (75,381) (25,527) (25,198) (85,995) (102,209) (109,375) (116,715) 226,698 87,478 186,417 238,312 - 13,854 87,478 186,417 238,312 -	3.1% 12/9/2022 12/31/2022 138.49 52,530.24 30.51 'both terminal methods	3.1% 129/2022 123/12/022 138.49 52,530.24 30.51 'both terminal methods Weight Terminal Value 50% 5,976,298 50% 21.386,316 13,681,307 13,681,307 Entry 2022 2023 2024 2025 2026 2027 12/09/2022 12/31/2022 12/31/2023 12/31/2024 12/31/2026 12/31/2026 12/31/2026 0.06 1.00 1.00 1.00 1.00 1.00 1.00 267,529 304,780 369,985 438,959 518,997 603,554 179,633 202,491 246,140 299,482 356,480 420,014 52,667 62,576 73,181 80,743 92,504 101,167 232,300 285,088 321,320 380,225 448,984 521,181 80,393 (75,381) (25,571) (21,855) (28,703) (85,995) (102,209) (109,375) (116,715) (124,824) (133,377) <td< td=""><td>3.3% 1292022 1231/2022 138.49 52.50.24 30.51 :both terminal methods </td></td<>	3.3% 1292022 1231/2022 138.49 52.50.24 30.51 :both terminal methods

Sensitivity Data	
WACC	10.6%
Terminal G	3.1%
Exit Multiple	30.51
COGS (healthcare)	(33.0)%
COGS (non-healthcare)	(60.0)%
SG&A expense	(31.0)%
R&D expense	(9.5)%
Target Price	145.43

WACC & Terminal G

	 WACC						
	\$ 145.43	11.6%	11.1%	10.6%	10.1%	9.6%	
_	2.3%	131.31	136.59	142.23	148.31	154.89	
wth	2.7%	132.45	137.90	143.75	150.07	156.96	
owt	3.1%	133.71	139.34	145.43	152.04	159.29	
Gro	3.5%	135.08	140.94	147.29	154.25	161.92	
	3.9%	136.60	142.71	149.39	156.74	164.93	

WACC & Exit Multiple

				WACC		
	145.43	11.6%	11.1%	10.6%	10.1%	9.6%
e	26.51	120.08	125.33	131.03	137.23	144.06
ltip	28.51	126.89	132.34	138.23	144.64	151.67
Mu	30.51	133.71	139.34	145.43	152.04	159.29
cit –	32.51	140.52	146.34	152.63	159.44	166.90
Ώ	34.51	147.33	153.35	159.83	166.85	174.51

COGS of each segment for final year

		COGS (healthcare)							
	145.43	(35.0)%	(34.0)%	(33.0)%	(32.0)%	(31.0)%			
r 😕	(62.0)%	128.40	134.06	139.73	145.39	151.06			
(non- icare)	(61.0)%	131.25	136.91	142.58	148.24	153.91			
	(60.0)%	134.10	139.76	145.43	151.09	156.76			
COGS health	(59.0)%	136.95	142.61	148.28	153.94	159.61			
õ f	(58.0)%	139.80	145.46	151.13	156.79	162.46			

SG&A and R&D for final year

and Rob for final year								
	SG&A Expense							
	145.43	(32.0)%	(31.5)%	(31.0)%	(30.5)%	(30.0)%		
	(10.5)%	128.82	132.97	137.12	141.27	145.43		
D SE	(10.0)%	132.97	137.12	141.27	145.43	149.58		
R&	(9.5)%	137.12	141.27	145.43	149.58	153.73		
шЩ	(9.0)%	141.27	145.43	149.58	153.73	157.88		
	(8.5)%	145.43	149.58	153.73	157.88	162.04		

Sensitivity Data	
WACC	10.6%
Terminal G	3.1%
Exit Multiple	30.51
COGS (healthcare)	(33.0)%
COGS (non-healthcare)	(60.0)%
SG&A expense	(31.0)%
R&D expense	(9.5)%
Target Price	145.43

WACC & Terminal G

	 WACC						
	\$ 145.43	11.6%	11.1%	10.6%	10.1%	9.6%	
_	2.3%	131.31	136.59	142.23	148.31	154.89	
wth	2.7%	132.45	137.90	143.75	150.07	156.96	
owt	3.1%	133.71	139.34	145.43	152.04	159.29	
Gro	3.5%	135.08	140.94	147.29	154.25	161.92	
	3.9%	136.60	142.71	149.39	156.74	164.93	

WACC & Exit Multiple

				WACC		
	145.43	11.6%	11.1%	10.6%	10.1%	9.6%
e	26.51	120.08	125.33	131.03	137.23	144.06
Į	28.51	126.89	132.34	138.23	144.64	151.67
Mu	30.51	133.71	139.34	145.43	152.04	159.29
L L	32.51	140.52	146.34	152.63	159.44	166.90
ũ	34.51	147.33	153.35	159.83	166.85	174.51

COGS of each segment for final year

			CC	OGS (healthca	re)	
	145.43	(35.0)%	(34.0)%	(33.0)%	(32.0)%	(31.0)%
r 😕	(62.0)%	128.40	134.06	139.73	145.39	151.06
(non- icare)	(61.0)%	131.25	136.91	142.58	148.24	153.91
	(60.0)%	134.10	139.76	145.43	151.09	156.76
COGS health	(59.0)%	136.95	142.61	148.28	153.94	159.61
õ f	(58.0)%	139.80	145.46	151.13	156.79	162.46

SG&A and R&D for final year

and KoD for fi	naiyear					
			5	SG&A Expense)	
	145.43	(32.0)%	(31.5)%	(31.0)%	(30.5)%	(30.0)%
	(10.5)%	128.82	132.97	137.12	141.27	145.43
R&D (pense	(10.0)%	132.97	137.12	141.27	145.43	149.58
	(9.5)%	137.12	141.27	145.43	149.58	153.73
α θ Β	(9.0)%	141.27	145.43	149.58	153.73	157.88
—	(8.5)%	145.43	149.58	153.73	157.88	162.04

Relative Valuation

Consumer Electronics Companies		Market data						Financial Estimates (FY23)				Trading Metrics			
Company Name	Ticker	Share price	Shares (MM)	Market Cap (MM)	Net Debt (MM)	Enterprise Value (MM)	Revenue (MM)	EBITDA (MM)	EBIT (MM)	Net Income (MM)	EVRevenue	EVIEBITDA	EVIEBIT	PIE	
MASIMO CORPORATION (XNAS:MASI)	XNAS:MASI	130.00	52.5	6,828.9	818.7		2,400.1	304.8	242.2	154.1	3.19	25.09	31.58	44.3	
SONOS, INC. (XNAS:SONO)	XNAS:SONO	17.67	127.3	2,248.5	(238.7		1,733.0	171.0	115.0	14.6	1.16	11.75	17.48	154.0	
T VIZIO HOLDING CORP. (XNYS/VZIO)	XN YS:VZIO	11.32	117.6	1,331.7	(310.3		1,901.0	85.6	38.5	32.0	0.54	11.93	26.53	41.6	
TURTLEBEACH CORPORATION (XNASHEAR)	XNAS:HEAR	8.86	16.6	146.7	41.9		286.0	16.6	(3.7)	(3.4)	0.66	11.36	N/A	N.	
UNIVERSAL ELECTRONICS INC. (XNASUEIC)	XNAS:UEIC	22.24	12.7	282.0	44.2	326.2	549.0	68.1	47.3	22.0	0.59	4.79	6.90	12.8	
MINOWLESCORPORATION (XNYSKN)	XN YS:KN	15.08	91.0	1,371.5	54.4	1,425.9	792.0	203.0	143.0	78.7	1.80	7.02	9.97	17.4	
Genasys Inc. (XNAS:GNSS)	XNAS:GNSS	3.10	36.6	113.5	(11.1	102.4	58.2	4.9	(0.1)	(0.2)	1.76	21.12	NA	N/	
DOLBY LABORATORIES, INC. (XNYSDLB)	XNYS:DLB	70.37	59.9	4,213.1	(758.4	3,454.7	1,277.0	475.0	248.0	209.0	2.71	7.27	13.93	20.1	
III VOXX INTERNATIONAL CORPORATION (XNAS/VOXX)	XNAS:VOXX	10.28	21.7	222.9	36.8	259.6	583.0	8.5	(4.9)	0.6	0.45	30.55	N/A	353.7	
Average									(1.21	13.22	14.96	99.9	
Min											0.45	4.79	6.90	12.8	
25th percentile											0.58	7.21	9.97	18.1	
Median											0.91	11.56	13.93	30.81	
75th percentile											1.77	14.23	17.48	125.9	
Max											2.71	30.55	26.53	353.76	
											2.0.1	00.00	20.00	000.11	
MedTech Companies				Market data				Financial Estim	ates (FY23)			Trading Me	etrics		
Company Name	Ticker	Share price	Shares (MM)	Market Cap (MM)	Net Debt (MM)	Enterprise Value (MM)	Revenue (MM)	EBITDA (MM)	EBIT (MM)	Net Income (MM)	EVRevenue	EVIEBITDA	EVIEBIT	PE	
I MASIMO CORPORATION (XNAS/MASI)	XNAS:MASI	130.00	52.5	6,828.9	818.7	7,647.6	2,400.1	304.8	242.2	154.1	3.19	25.09	31.58	44.33	
NOVOCURELIMITED (XNAS/NVCR)	XNAS:NVCR	82.25	105.0	8,632.1	(390.8	8,241.3	555.0	(104.0)	(94.7)	(102.0)	14.85	NA	NA	N.9	
TELEFLEX INCORPORATED (XNYS:TFX)	XNYS:TFX	219.17	46.9	10,281,3	1,384,2	11,665.5	2,916.0	873.0	797.0	503.0	4.00	13.36	14.64	20.44	
HOLOGIC.INC. (XNASHOLX)	XNAS:HOLX	75.93	245.8	18,665,9	540.0	19,205.9	3,818.0	1247.0	1,145.0	903.0	5.03	15.40	16.77	20.67	
INSPIRE MEDICAL SYSTEMS, NC. (XNYSINSP)	XNYS:NSP	215.33	28.9	6,220.9	(418.4	5,802.5	513.0	(45.7)	(75.6)	(75.0)	11.31	NA	NA	NØ	
PENUMBRA INC. (XNYSPEN)	XNYS:PEN	194.02	38.0	7,368.9	33.1	7,402.0	1,003.0	78.2	52.4	41.1	7.38	94.65	141.26	179.29	
III SHOCKWAVE MEDICAL, INC. (XNAS:SWAV)	XNAS:SWAV	246.6	36.1	8,912,1	(196.0		634.0	218.0	178.0	145.0	13.75	39,98	48.97	61,46	
ABIOMED. INC. (XNASABMD)	XNAS:ABMD	373.99	45.1	16,863,2	(820.4		1,136.0	291.0	266.0	273.0	14.12	55.13	60.31	61.77	
DEXCOM, NC. (XNASDXCM)	XNAS:DXCM	115.96	386.3	44,790.7	(240.0		3,472.0	901.0	609.0	362.0	12.83	49.45	73.15	123.73	
III LINANOVA PLC (XNASLINN)	XNASLIVN	52.11	53.5	2,788.9	346.7		1,045.0	189.0	159.0	37.3	3.00	16.59	19.72	74.77	
EXACT SCIENCES CORPORATION (XNASEXAS)	XNASEXAS	46.33	177.7	8,231.9	1,790.9		2,282.0	(116.0)	(408.0)	(437.0)	4,39	NA	N/A	N/	
Average	ANNO.EANO	40.33	111.1	0,231.0	1,700.0	10,022.8	2,202.0	(110.0)	(408.0)	(437.0)	9.07	40.65	53.55	77.4	
Min											3.00	13.36	14.64	20.4	
25th percentile											4.55	16.00	18.25	41.07	
Median											9.35	39.98	48.97	61.77	
75th percentile											13.52	52.29	66.73	99.25	
Max											13.52	94.65	141.26	179.25	
HIGA .											14.00	34.00	141.20	118.20	
		Blended Trading	Metrics												
		Weight													
		Consumer Electr	onics			33.3%									
		Medtech				66.7%									

	EV/Revenue	EV/EBITDA	EV/EB IT	P/E
Average	6.45	31.51	40.68	84.95
Min	2.15	10.51	12.06	17.90
25th percentile	3.23	13.07	15.49	33.41
Median	6.53	30.51	37.29	51.48
75th percentile	9.60	39.60	50.31	108.14
Max	10.80	73.28	103.02	237.45
MASI	3.19	25.09	31.58	44.33

MASI	Target	Price	

11 MASIMO CORPORATION (XNASMASI) 11 MASIMO CORPORATION (XNASMASI) 11 MASIMO CORPORATION (XNASMASI) 12 MASIMO CORPORATION (XNASMASI)

			MASI's Implied Valuation				MASI's FY23				Peers		
Approach	Share price	Shares (MM)	Market Cap (MM)	Net Debt (MM)	Enterprise Value (MM)	Revenue (MM)	EBITDA (MM)	EBIT (MM)	Net Income (MM)	EV/Revenue	EVIEBITDA	EVIEBIT	P/E
EVRevenue	282.92	52.5	14,861.94	818.7	15,680.6	2,400.1	304.8	242.2	154.1	6.53			
EVIEBITDA	161,42	52.5	8,479,38	818.7	9,298,1	2,400,1	304.8	242.2	154.1		30.51		
EVIEBIT	156.34	52.5	8,212.58	818.7	9,031.3	2,400.1	304.8	242.2	154.1			37.29	